Ливарол

Quick links

Choose a section

Quick links to important sections

Advertisements

Ливарол

Selected form

Advertisements
Advertisements

Overview of Ливарол

Quick Facts: Ливарол Identity

Property Description
Active Ingredient Кетоконазол (Ketoconazole)
Form Суппозитории вагинальные (Vaginal Suppositories)
Pharmacological Class Противогрибковое средство (Antifungal Agent)
Common Use Management of грибковые инфекции (Fungal Infections)
Origin Синтетическое (Synthetic)
Differentiating Feature Targeted local application via Macrogol base

What Type of Medicine is Ливарол and What is its Purpose?

Ливарол is a синтетическое (synthetic) лекарственный препарат (medicinal product) primarily classified as a противогрибковое средство (antifungal agent) intended for местное применение (local application). Its general purpose is the management of грибковые инфекции (fungal infections).

Its active substance, Кетоконазол (Ketoconazole), belongs to the азолы (azoles) group, categorized as an imidazole derivative. This classification relates to the drug's mechanism against various pathogenic fungi. This mechanism, which involves disrupting the fungal cell structure, is recognized for its targeted antifungal efficacy. This makes the medicine an established therapeutic option for addressing localized fungal conditions, such as вагинальный кандидоз (vaginal candidiasis), a typical scenario for its use.

Кетоконазол in Ливарол: Composition and Dosage Form

The essential component of Ливарол is the active substance Кетоконазол, which is formulated exclusively as суппозитории вагинальные (vaginal suppositories) for targeted delivery.

Ливарол is a монопрепарат (single-ingredient product), structured for интравагинально (intravaginal) use, making the суппозитории вагинальные form a distinctive feature for local therapy. Кетоконазол is integrated into a hydrophilic base primarily composed of Макрогол 1500 and Макрогол 400. The choice of the Макрогол base ensures the uniform release of the active Кетоконазол upon contact with body temperature, enabling the concentrated местное применение necessary to address the source of the infection directly. This formulation choice differentiates it from topical creams or oral tablets containing the same active substance.

Advertisements

What side effects are possible with Ливарол?

Possible Side Effects and Safety Information

The safety profile of Ливарол (Ketoconazole vaginal suppositories) is primarily defined by its local application and negligible systemic absorption, which is an important distinction noted in regulatory documents. This local use profile means the severe systemic adverse reactions, such as hepatotoxicity (liver damage) and adrenal suppression, that are associated with oral Ketoconazole tablets do not apply to this local formulation.


Official Adverse Reactions and Frequency

Adverse effects listed in regulatory documents are mainly localized to the site of application. These reactions are categorized by frequency based on clinical data:

  • Common Reactions: The most frequently documented adverse effects are local application site events, such as a burning sensation, itching (pruritus), and erythema (redness). These are generally mild and localized.
  • Uncommon/Other Reactions: Other localized discomforts, including discharge, pain, or irritation, have been reported.
  • Rare Serious Reactions: The possibility of severe hypersensitivity reactions, including anaphylaxis, is a rare but documented risk for any medication containing this active substance.

Population and Use Restrictions

Official safety documentation provides specific constraints on use:

  • Contraindication: The medicine is contraindicated in individuals with a known history of sensitivity or allergy to ketoconazole or any of the inactive ingredients.
  • Pediatric Use: The safety and effectiveness of this formulation have not been established in children under 12 years of age, as noted in regulatory texts for topical use.
  • Pregnancy and Lactation: While systemic absorption is low, official labels indicate that use during breastfeeding or pregnancy should be determined by weighing the potential benefits against the risks, given the lack of adequate studies in these groups.

Note: Regulatory guidelines require that if signs of increasing local irritation or a worsening of the underlying condition occur, use of the medicine should be discontinued.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Ливарол (Ketoconazole vaginal suppositories) addresses overdose based on the product’s limited systemic absorption. Due to the intravaginal route and negligible uptake of the active substance, systemic toxicity is considered highly unlikely with correct use.

Documented overdose manifestations are localized, primarily presenting as a burning sensation and irritation at the application site. If severe local reactions occur, regulatory guidance mandates that the product should be discontinued, and medical advice should be sought for further symptomatic and supportive measures.

The primary regulatory concern for serious outcomes is related to accidental oral ingestion of the suppositories. In this specific circumstance, immediate medical attention must be sought, and a poison control center should be contacted.

For managing any overdose event, treatment consists solely of symptomatic and supportive measures, as no specific antidote for Ketoconazole is known. For cases of accidental oral ingestion, procedural steps such as gastric lavage or the administration of activated charcoal may be considered by healthcare providers within the first hour. This approach reflects the required intervention strategy documented in official prescribing information.

Advertisements

Therapeutic Uses of Ливарол

What Ливарол Treats: Main Uses and Benefits

Ливарол is commonly used to help manage vulvovaginal candidiasis, generally known as a vaginal yeast infection. The medication is applied across therapeutic domains involving conditions characterized by periods of heightened symptoms caused by fungal activity. It is used in situations where additional symptomatic support is needed.


Treatment and Symptom Relief

This treatment is commonly used across conditions presenting with acute episodes and is relevant in situations involving recurrent or episodic manifestations. It helps address symptom clusters that may become intense or disruptive, including localized itching, burning, soreness, and irritation. It is applied in situations involving certain distressing symptoms associated with fungal overgrowth.

Symptomatic relief helps patients cope more steadily with difficult episodes, contributing to easing the overall symptom load. The treatment may be relevant when symptoms create noticeable physiological strain or interfere with daily comfort.

“The treatment assists with maintaining functional stability by providing supportive symptom relief.”

Quick Fact: Relief for Symptoms related to inflammatory or irritative states

Regulatory References

  1. National Institutes of Health (NIH) ClinicalTrials.gov registry
Advertisements

Eligibility and Restrictions for Use

Official Eligibility: Who Can and Cannot Use Ливарол

This section outlines the population eligibility and non-eligibility for Ливарол (Кетоконазол vaginal suppositories), as defined by official governmental regulatory documentation.


Eligibility Status by Population

The medicine is intended for use by adult females 18 years of age and older who do not have any official contraindications.

Population Group Regulatory Status
Pediatric (Under 18 Years) Contraindicated
Pregnancy Contraindicated
Lactation/Breastfeeding Contraindicated (Use requires discontinuation of breastfeeding)
Hypersensitivity to Components Contraindicated

Condition-Based Eligibility Restrictions

Use is subject to limitation in patients diagnosed with severe renal insufficiency or severe hepatic insufficiency, as documented in prescribing information. Limitations also apply to individuals with decreased function of the adrenal cortex and pituitary.

The official eligibility profile is strictly defined by these mandatory exclusions and restrictions. All use must align with the specific constraints documented in the medicine's official labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Ливарол is a locally administered antifungal product containing ketoconazole. Due to its specific route of application (typically topical or vaginal) and minimal systemic absorption into the bloodstream, the risk of clinically significant drug-drug interactions is considered low, especially when compared to oral ketoconazole formulations.

However, ketoconazole is known to be a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. This enzyme is responsible for metabolizing—or breaking down—a large number of other medicines. Although systemic concentrations are low with local use, a theoretical potential exists for increasing the concentration of co-administered drugs that are highly sensitive to CYP3A4 inhibition and possess a narrow therapeutic window.

Category of Potential Interaction Mechanism and Clinical Relevance
Medicines metabolized by CYP3A4 Ketoconazole may inhibit the metabolism of certain co-administered drugs, but this risk is low due to limited systemic exposure.

For most locally administered ketoconazole products, no specific restrictions or timing-based separation requirements are officially mandated for drug interactions. Patients who are concurrently taking other medications, particularly those with serious potential interactions involving CYP3A4, should consult a healthcare professional.

Advertisements

Mechanism of Action

How Ливарол Works

The mechanism of Кетоконазол in Ливарол is defined by its selective interference with the structural integrity of the fungal cell, targeting the ergosterol biosynthesis pathway.


Primary Mechanism: Enzymatic Inhibition of Ergosterol Synthesis

Кетоконазол functions as an inhibitor of the fungal enzyme cytochrome P450 14α-demethylase. This action directly blocks the conversion of lanosterol into ergosterol within the ergosterol biosynthesis pathway. The resulting depletion of ergosterol and accumulation of toxic sterol intermediates are the initial molecular consequences of the drug's interaction with its target enzyme.


Cellular Consequence: Membrane Destabilization and Lysis

The altered sterol profile fundamentally disrupts the lipid composition of the cell membrane, severely increasing its permeability and causing a loss of structural rigidity. This structural failure leads to osmotic imbalance and subsequent breakdown (lysis) of the pathogenic fungal cell, resulting in fungicidal and fungistatic cellular effects. The action is primarily targeted at fungal organisms and also exhibits secondary inhibitory effects against certain Gram-positive bacteria.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Ливарол — Official Administration Guidelines

Administration Scope

Entity Instruction
Route of administration Intravaginal use only (Интравагинально).
Dosing schedule 1 suppository (400 mg Ketoconazole) per day (1 суппозиторий в сутки).
Timing in relation to meals (if applicable) Not applicable (local route); administered before bedtime (на ночь).
Preparation requirements (if applicable) The suppository must be removed from its contour packaging (Извлеките суппозиторий из контурной упаковки).
Age-group administration rules Pediatric patients: Use is generally not recommended or experience is absent. Pregnancy (II–III trimester): The dosage regimen is specified as usual/standard (обычные) when use is determined appropriate by a healthcare professional.
Missed-dose rules The full course of treatment must not be interrupted (Не следует прерывать курс лечения самостоятельно).
Special procedural conditions The suppository must be inserted deeply into the vagina while the user is lying on the back (В положении лежа на спине).

Instruction Classifications (High-Level)

Entity Classification
Administration method type Topical/local route, specifically intravaginal.
Frequency pattern Once daily (1 раз/сут).
Use-context constraints Duration is explicitly set based on the type of condition: 3–5 days (acute) or 10 days (chronic recurrent).

Resulting Procedural Structure

The official instructions detail a specific sequence for use:

  • Remove the vaginal suppository from the protective packaging.
  • Lie on the back in a reclined position.
  • Insert one suppository deeply into the vagina, preferably before sleep.
  • Continue the once-daily regimen for the full, prescribed course (3–10 days).

Connection to the Overall Use Protocol

The official instructions establish a fixed local administration protocol centered on a uniform 400 mg daily dose via the intravaginal route. This protocol dictates the required administration conditions, such as the timing and user position, to maximize local retention of the active substance. Furthermore, the instructions mandate that the fixed course duration—either 3–5 days for acute use or 10 days for recurrent use—be fully completed, regardless of symptom status, as a critical procedural constraint.

Advertisements

Recent Clinical Evidence

Research Evidence: Ketoconazole (Ливарол)

Studies of topical formulations containing ketoconazole (the active substance in Ливарол) have focused on their application for cutaneous candidiasis and dermatomycosis. The available research generally involves clinical trials designed to assess the presence or absence of fungal pathogens following treatment protocols.

Efficacy and Study Endpoints

Clinical research has documented the proportion of participants achieving mycological cure—the absence of the causative fungal organism in culture or microscopic examination. These studies often compare the outcomes of topical ketoconazole against a placebo or another antifungal agent.

  • Treatment Duration: Trials typically evaluate ketoconazole use over treatment periods ranging from 7 to 14 days, dependent on the condition being studied.
  • Key Finding: Results from various studies suggest that treatment protocols involving ketoconazole are associated with a greater likelihood of achieving mycological cure compared to a placebo. Findings regarding symptomatic improvement (such as reduced itching or irritation) are also recorded as secondary endpoints.

Safety and Tolerability

Information regarding patient safety was collected across all clinical development stages. The available data primarily relates to localized skin reactions at the application site.

Observation Category Reported Study Findings
Local Reactions Documentation of minor application-site irritation, burning sensation, or erythema (redness).
Systemic Exposure Minimal systemic absorption of ketoconazole was reported after topical application.

Overall, the documented safety findings from trials support the localized action of the drug when used as a topical cream or suppository, with the most common events being application-site reactions.

Key Studies & References

  1. FDA Label: KETOCONAZOLE cream (Dailymed - NIH)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ливарол (FAQ)


Q: Can Ливарол be used by men?

Official product information for Ливарол (Ketoconazole vaginal suppositories) specifies that the intended user population is adult females 18 years of age and older. The official labeling does not address use outside of this specific demographic.

Q: Can Ливарол be taken with pain relievers like ibuprofen or paracetamol?

Due to the local application of the product, the amount of medicine that enters the bloodstream is minimal. Official information notes that this minimal systemic absorption significantly lowers the potential for drug-drug interactions, which is a greater concern with oral forms of the active substance.

Q: Does alcohol interact with Ливарол?

Official warnings regarding alcohol interaction are documented for the oral form of ketoconazole. However, because this product is administered locally and has negligible systemic absorption, official information suggests this risk is significantly reduced or considered irrelevant for the vaginal suppository.

Q: Can Ливарол affect the effectiveness of birth control pills?

The active substance in Ливарол is known to potentially interact with certain medications that are metabolized by the liver. Due to the low systemic absorption achieved with the local application of the suppository, official information indicates this theoretical interaction risk is minimal.

Q: What should I do if I miss a use of Ливарол?

Official guidelines emphasize that the full course of treatment should not be interrupted. General information for the active substance suggests using the dose when it is remembered, or skipping it if it is near the next scheduled time. The full prescribed course should not be interrupted.

Q: What precautions should be taken when using Ливарол with chronic conditions?

Official prescribing information notes that use is subject to restrictions for individuals diagnosed with certain chronic conditions. These include limitations on use in patients with severe renal insufficiency (kidney problems) and severe hepatic insufficiency (liver problems), as well as decreased function of the adrenal cortex and pituitary.

Q: Can I use Ливарол if I have a history of liver problems?

Information regarding the use of Ливарол with liver problems is defined by official labeling. Official regulatory information identifies severe hepatic insufficiency as a condition that restricts the use of this product. While the severe systemic risks associated with oral ketoconazole are not applicable to the local formulation, this restriction remains in the official guidance.

Q: Does the official guidance mention any warning signs to look out for while using Ливарол?

Yes, official safety documentation notes specific signs to monitor. If a user experiences signs of increasing local irritation or a worsening of the underlying condition, official guidance describes that the discontinuation of use is indicated in the prescribing information.

Q: Is Ливарол considered an antibiotic?

Ливарол is formally classified as an antifungal agent and belongs to the imidazole derivative class. Although the active substance, ketoconazole, exhibits secondary inhibitory effects against some Gram-positive bacteria, its primary use and classification in official documents is as a targeted treatment for fungal infections.

Q: How quickly does Ливарол typically start to work?

Regulatory guidance for similar topical products containing the active substance suggests that clinical improvement may be seen fairly soon after beginning treatment. The full recommended treatment course is indicated regardless of how quickly improvement is perceived.

Q: How long after starting Ливарол might one notice a change?

Information for similar topical ketoconazole products suggests that noticeable change or clinical improvement may be seen fairly soon. Official guidelines indicate that the entire course of treatment is to be completed to address the infection fully, even if symptomatic improvement is perceived early.

Q: Are there any serious but rare side effects associated with Ливарол?

Official safety documentation confirms that the possibility of severe hypersensitivity reactions, including anaphylaxis, is a rare but documented risk associated with the active substance in this product.

Q: What does official information say about the success rate of Ливарол?

Official research focuses on the mycological cure rate, which is the absence of the causative fungal organism upon testing. Studies generally suggest that treatment is associated with a greater likelihood of achieving mycological cure compared to a placebo.

Q: What is the difference between Ливарол and similar products I see advertised?

Ливарол is officially defined as a single-ingredient product (monopreparation) containing only Ketoconazole, and is formulated exclusively as vaginal suppositories. This specific form ensures targeted local delivery using a Macrogol base, which is its key distinguishing feature.

Q: What does it mean if my symptoms seem to return after using Ливарол?

Research evidence documents the possibility of mycological positivity, meaning the return of the fungal organism, after the initial treatment period. Official instructions specify that the full, fixed course of use is to be completed to address the potential for recurrence.

Q: What makes Ливарол different from a prescription-only alternative?

This product is distinguished by its specific design as a vaginal suppository for local delivery, containing only Ketoconazole. This targeted application results in minimal systemic absorption, which is a key pharmacological difference compared to alternatives designed for systemic treatment.

Q: Are there risk factors that make side effects more likely with Ливарол?

The primary risk factor identified in official documentation is a known history of sensitivity or allergy to ketoconazole or any of the product's inactive ingredients. A known allergy to the components is listed as a contraindication in the official product information.

Q: Does the way I use Ливарол affect how well it works?

Yes, official regulatory instructions detail a specific protocol for administration, including the need to insert the suppository deeply into the vagina while lying on the back. This established procedure is designed to maximize local retention and effective delivery of the active substance.

Q: Are there any components in Ливарол that people are commonly allergic to?

Official prescribing information indicates that a known history of sensitivity or allergy to the active substance ketoconazole or any of the inactive ingredients (excipients) is a contraindication. Information for similar formulations notes that sensitivity to excipients is possible.

Q: Is it normal to feel better after only a couple of days of using Ливарол?

Official guidance for similar topical products suggests that clinical improvement may be seen fairly soon after beginning treatment. Official guidance emphasizes that the full prescribed course is to be completed, regardless of early symptomatic improvement, to fully address the infection.

Q: Is the dosage strength of Ливарол always the same?

Official regulatory documents define the standard dosing schedule for this product as one suppository containing 400, mg of Ketoconazole per day. This is the uniform strength described in the product's official labeling.

Q: Why do some sources describe Ливарол as a broad-spectrum agent?

The active substance, ketoconazole, is officially described in pharmacological texts as a broad-spectrum synthetic antifungal agent. This is because it is known to be active against a wide variety of common dermatophytes and yeasts, including Candida species, the typical cause of the infections it is used for.

Q: Are there any dietary restrictions to be aware of when using Ливарол?

General guidance for the active substance indicates that, unless specific advice is provided by a healthcare professional, users should continue their normal diet. Dietary changes are not typically required for this locally acting product.

Advertisements

How should Ливарол be stored and disposed of?

How to Store and Dispose of Ливарол

Storage of Ливарол (Ketoconazole vaginal suppositories) must adhere strictly to labeled regulatory requirements to maintain product integrity.

Official Storage Conditions

Requirement Specification
Temperature Store at a temperature not exceeding 25 C
Environmental Protect from light and store in a dry place
Packaging Must be kept in the original container and avoid freezing
Child Safety Keep out of the sight and reach of children

Disposal Requirements

The product must not be used after its labeled expiration date. For disposal of unused or expired suppositories, consult a pharmacist or healthcare professional for guidance on take-back programs and environmental safety. Unwanted medicine should not be discarded into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ливарол found in:

A-Z Index: